All articles tagged with #dmts
A French study found women with relapsing-remitting MS aged 18-40 are significantly less likely than men to receive disease-modifying therapies, despite evidence supporting their safety during pregnancy. The gap persists even after accounting for pregnancy-related treatment discontinuation, highlighting the need for better education on treatment guidelines to prevent long-term disability in women.
A survey of neurologists in the U.S. rates Kesimpta, Ocrevus, and Briumvi as the best disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS). The ketogenic diet has shown potential benefits for people with RRMS, including reduced body fat, improved symptoms, and increased exercise capacity, but adherence can be challenging. A real-world study in Turkey suggests that a generic version of Gilenya is safe and effective, although long-term data is needed to maintain confidence in generic MS treatments.
The American Academy of Neurology (AAN) 2023 Annual Meeting presented several studies on MS treatments, including stem cell therapy, which showed positive results in reducing disease activity and improving walking ability. Early use of Aubagio was also found to reduce the risk of developing MS symptoms in patients with radiologically isolated syndrome. Additionally, follow-up studies on DMTs Kesimpta and Tolebrutinib showed stable disability levels and low relapse rates.